Table 1.
Characteristics of the 182 patients enrolled in the studya
| Variable | NTM patient, n (%) |
Non-NTM patient, n (%) |
p-Value |
|---|---|---|---|
| Age >65 years | 45 (66) | 23 (46) | 0.0150 |
| Male | 11 (16) | 30 (34) | 0.0120 |
| Diagnosis delay >12 months | 29 (45) | 34 (42) | 0.6870 |
| Diagnosis delay >24 months | 34 (53) | 46 (56) | 0.6600 |
| BMI >30 kg/m2 | 3 (11.5) | 34 (33) | 0.4000 |
| Sputum production | 48 (72) | 56 (65) | 0.3530 |
| Hemoptysis | 20 (30) | 17 (20) | 0.1510 |
| Cough | 65 (97) | 75 (87) | 0.0470 |
| Dyspnea | 34 (51) | 40 (47) | 0.6030 |
| Chest pain | 2 (3) | 4 (5) | 0.4720a |
| Cancer | 9 (17) | 8 (10) | 0.2160 |
| GERD | 7 (14) | 6 (7) | 0.2580 |
| COPD | 4 (8) | 8 (10) | 0.6690a |
| DM | 1 (2) | 7 (9) | 0.1520a |
| Current smoker | 3 (4) | 12 (14) | 0.3090a |
| Childhood pulmonary infection | 24 (36.4) | 23 (27) | 0.2220 |
| Pneumonia | 22 (40) | 23 (35.9) | 0.6490 |
| Family history of bronchiectasis | 3 (4.4) | 1 (1.1) | 0.3200a |
| PFT obstructive defect | 7 (39) | 34 (51) | 0.3740 |
| PFT restrictive defect | 4 (27) | 23 (39) | 0.5500a |
| Bronchiectasis seen in CXR | 22 (33) | 22 (26) | 0.3490 |
| IV antibiotic therapy | 4 (6) | 16 (18) | 0.0290a |
| Clearance device | 31 (46) | 11 (12) | <0.0001 |
| Flutter valve used | 29 (43) | 2 (2.3) | <0.0001a |
| Mortality | 1 (2) | 5 (6) | 0.1610a |
NTM, non-tuberculous mycobacteria; BMI, body mass index; GERD, gastroesophageal reflux disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; PFT, pulmonary function tests; CXR, chest X-ray; IV, intravenous.
a
Data are number (%) of patients.
bFisher’s exact test.